Pathologic complete response and survival in early-stage HER2-positive breast cancer patients treated with or without anthracyclines
{{output}}
The development of novel human epidermal growth factor receptor type-2 (HER2)-targeted therapies for HER2-positive breast cancer (HER2+ breast cancer (BC)) in recent decades has called for a reassessment of the benefit of including anthracyclines in neoadjuvan... ...
